Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 4
1951 1
1952 1
1953 4
1954 2
1955 2
1956 1
1985 1
1987 1
1988 1
1989 1
1990 2
1991 1
1993 4
1994 2
1995 3
1996 4
1998 4
1999 3
2000 1
2001 1
2002 5
2003 7
2004 6
2005 5
2006 4
2007 8
2008 9
2009 6
2010 8
2011 7
2012 7
2013 7
2014 13
2015 7
2016 10
2017 7
2018 9
2019 3
2020 10
2021 10
2022 8
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J; EMPRISE Europe and Asia Study Group. Karasik A, et al. Among authors: carstensen b. Diabetes Metab. 2023 Mar;49(2):101418. doi: 10.1016/j.diabet.2022.101418. Epub 2023 Jan 3. Diabetes Metab. 2023. PMID: 36608816 Free article.
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.
Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, Pedersen O. Gæde P, et al. Among authors: carstensen b. Diabetologia. 2016 Nov;59(11):2298-2307. doi: 10.1007/s00125-016-4065-6. Epub 2016 Aug 16. Diabetologia. 2016. PMID: 27531506 Free PMC article. Clinical Trial.
The epidemiology of diabetes and cancer.
Carstensen B, Jørgensen ME, Friis S. Carstensen B, et al. Curr Diab Rep. 2014 Oct;14(10):535. doi: 10.1007/s11892-014-0535-8. Curr Diab Rep. 2014. PMID: 25156543 Review.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Among authors: carstensen b. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
Register-based studies of diabetes.
Carstensen B, Borch-Johnsen K. Carstensen B, et al. Scand J Public Health. 2011 Jul;39(7 Suppl):175-9. doi: 10.1177/1403494811404279. Scand J Public Health. 2011. PMID: 21775379 Review.
The National Diabetes Register.
Carstensen B, Kristensen JK, Marcussen MM, Borch-Johnsen K. Carstensen B, et al. Scand J Public Health. 2011 Jul;39(7 Suppl):58-61. doi: 10.1177/1403494811404278. Scand J Public Health. 2011. PMID: 21775353
188 results